Discovery of 3-((3-amino-1H-indazol-4-yl)ethynyl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (AKE-72), a potent Pan-BCR-ABL inhibitor including the T315I gatekeeper resistant mutant

BCR-ABL inhibition is an effective therapeutic approach for the treatment of chronic myeloid leukaemia (CML). Herein, we report the discovery of AKE-72 (5), a diarylamide 3-aminoindazole, as a potent pan-BCR-ABL inhibitor, including the imatinib-resistant mutant T315I. A focussed array of compounds...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Damasy, Ashraf K., Kim, Hyun Ji, Park, Jung Woo, Nam, Yunju, Hur, Wooyoung, Bang, Eun-Kyoung, Keum, Gyochang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360995/
https://www.ncbi.nlm.nih.gov/pubmed/37470410
http://dx.doi.org/10.1080/14756366.2023.2228515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360995/
https://www.ncbi.nlm.nih.gov/pubmed/37470410
http://dx.doi.org/10.1080/14756366.2023.2228515

Ejemplares similares